Efficient introduction of specific tp53 mutations into mouse embryonic fibroblasts and embryonic stem cells

Nature Protocols

Volumn 7, Issue 6, 2012, Pages 1145-1160

  Wei, Quan Xiang ^a   Hoeven, Franciscus Van Der ^a   Hollstein, Monica ^a,b   Odell, Adam F ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANIMAL; ARTICLE; FETAL STEM CELL; FIBROBLAST; GENETICS; METHODOLOGY; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MOUSE; MUTATION; NUCLEOTIDE SEQUENCE; PLASMID; POLYMERASE CHAIN REACTION;

ANIMALS; BASE SEQUENCE; FETAL STEM CELLS; FIBROBLASTS; MICE; MOLECULAR BIOLOGY; MOLECULAR SEQUENCE DATA; MUTATION; PLASMIDS; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865816235     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2012.042     Document Type: Article

References (29)

1. Palmero, E. I., Achatz, M. I., Ashton-Prolla, P., Olivier, M., Hainaut, P., Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr. Opin. Oncol. 22, 64-69 (2010).
2. Breen, L., Heenan, M., Amberger-Murphy, V., Clynes, M., Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines., Anticancer Res. 27, 1361-1364 (2007).
3. Breen, L., Keenan, J., Clynes, M., Generation of lung cancer cell line variants by drug selection or cloning. Methods Mol. Biol. 731, 125-133 (2011).
4. Hollstein, M., et al., New approaches to understanding p53 gene tumor mutation spectra. Mutat. Res. 431, 199-209 (1999).
5. Cimoli, G., et al., Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs. Biochim. Biophys. Acta 1705, 103-120 (2004).
6. Milo, G. E., Shuler, C. F., Lee, H., Casto, B. C. A., conundrum in molecular toxicology: molecular and biological changes during neoplastic transformation of human cells. Cell Biol. Toxicol. 11, 329-345 (1995).
7. Wei, Q X., Odell, A. F., van der Hoeven, F., Hollstein, M., Rapid derivation of genetically related mutants from embryonic cells harboring a recombinase-specific Trp53 platform. Cell Cycle 10, 1261-1270 (2011).
8. Olivier, M., Hollstein, M., Hainaut, P., TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2, a001008 (2010).
9. Whibley, C., Pharoah, P. D., Hollstein, M., p53 polymorphisms: cancer implications. Nat. Rev. Cancer 9, 95-107 (2009).
10. Reinbold, M., et al., Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene 27, 2788-2794 (2008).
11. Song, H., Hollstein, M., Xu, Y., p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat. Cell Biol. 9, 573-580 (2007).
12. Luo, J. L., et al., Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20, 320-328 (2001).
13. Odell, A., Askham, J., Whibley, C., Hollstein, M., How to become immortal: let MEFs count the ways. Aging (Albany NY) 2, 160-165 (2010).
14. Whibley, C., et al., Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence. J. Biol. Chem. 285, 11326-11335 (2010).
15. Millau, J. F., Mai, S., Bastien, N., Drouin, R., p53 functions and cell lines: have we learned the lessons from the past? Bioessays 32, 392-400 (2010).
16. vom Brocke, J., Schmeiser, H. H., Reinbold, M., Hollstein, M., MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis 27, 2141-2147 (2006).
17. Liu, Z., et al., Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc. Natl. Acad. Sci. USA 101, 2963-2968 (2004).
18. Sur, S., et al., A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc. Natl. Acad. Sci. USA 106, 3964-3969 (2009).
19. Nedelko, T., et al., TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumors. Int. J., Cancer 124, 987-990 (2009).
20. Luo, J. L., et al., UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin. Cancer Res. 61, 8158-8163 (2001).
21. Barbaric, I., Dear, T. N., Culture of murine embryonic stem cells. Methods Mol. Biol. 561, 161-184 (2009).
22. Feng, L., Hollstein, M., Xu, Y., Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle 5, 2812-2819 (2006).
23. Ozenne, P., Eymin, B., Brambilla, E., Gazzeri, S., The ARF tumor suppressor: structure, functions and status in cancer. Int. J. Cancer 127, 2239-2247 (2010).
24. Niwa, H., Ogawa, K., Shimosato, D., Adachi, K., A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature 460, 118-122 (2009).
25. Ogawa, K., et al., Activin-Nodal signaling is involved in propagation of mouse embryonic stem cells. J. Cell Sci. 120, 55-65 (2007).
26. Ramirez, M. A., Pericuesta, E., Yanez-Mo, M., Palasz, A., Gutierrez-Adan, A., Effect of long-term culture of mouse embryonic stem cells under low oxygen concentration as well as on glycosaminoglycan hyaluronan on cell proliferation and differentiation. Cell Prolif. 44, 75-85 (2011).
27. Tang, W., et al., Faithful expression of multiple proteins via 2A-peptide self-processing: a versatile and reliable method for manipulating brain circuits. J. Neurosci. 29, 8621-8629 (2009).
28. Fernandes, T.G., Diogo, M.M., Fernandes-Platzgummer, A., da Silva, C. L., Cabral, J. M., Different stages of pluripotency determine distinct patterns of proliferation, metabolism, and lineage commitment of embryonic stem cells under hypoxia. Stem Cell Res. 5, 76-89 (2010).
29. Powers, D. E., Millman, J. R., Huang, R. B., Colton, C. K., Effects of oxygen on mouse embryonic stem cell growth, phenotype retention, and cellular energetics. Biotechnol. Bioeng. 101, 241254 (2008).